EAM
DNLI icon

Eagle Asset Management’s Denali Therapeutics DNLI Stock Holding History

Eagle Asset Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-315,520
Closed -$6.77M – 576
2023
Q4 		$6.77M Buy
315,520
+26,387
+9% +$523K 0.04% 335
2023
Q3 		$5.96M Sell
289,133
-5,658
-2% -$144K 0.04% 330
2023
Q2 		$8.7M Sell
294,791
-8,170
-3% -$230K 0.05% 281
2023
Q1 		$6.98M Sell
302,961
-26,123
-8% -$719K 0.04% 298
2022
Q4 		$9.09M Buy
329,084
+73,624
+29% +$2.19M 0.06% 249
2022
Q3 		$7.84M Sell
255,460
-8,244
-3% -$268K 0.05% 270
2022
Q2 		$7.76M Buy
263,704
+59,854
+29% +$1.57M 0.05% 283
2022
Q1 		$6.56M Buy
203,850
+12,334
+6% +$424K 0.03% 345
2021
Q4 		$8.63M Sell
191,516
-51,029
-21% -$2.42M 0.04% 332
2021
Q3 		$12.2M Sell
242,545
-48,558
-17% -$2.74M 0.06% 278
2021
Q2 		$22.8M Sell
291,103
-26,759
-8% -$1.66M 0.1% 226
2021
Q1 		$17.8M Buy
317,862
+18,676
+6% +$1.25M 0.08% 247
2020
Q4 		$25.1M Buy
+299,186
New +$18.1M 0.14% 205

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Eagle Asset Management's DNLI Position: Q1 2024 in Review

Eagle Asset Management sold out of Denali Therapeutics (DNLI) in Q1 2024, closing a stake of 315,520 shares — an estimated $6.77M sold.

Eagle Asset Management first reported a position in DNLI in Q4 2020 and held it in 13 quarters. The position peaked at $25.1M in Q4 2020. 210 funds tracked by Wall St. Rank hold DNLI as of Q1 2024.

  • Eagle Asset Management reported no remaining Denali Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Eagle Asset Management sold 315,520 Denali Therapeutics shares in Q1 2024, an estimated $6.77M.
  • Eagle Asset Management first reported a position in Denali Therapeutics in Q4 2020 and held it in 13 quarters.
  • Eagle Asset Management's Denali Therapeutics position peaked at $25.1M in Q4 2020.
  • 210 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2024.

Based on Eagle Asset Management's 13F filing for Q1 2024, filed 9 May 2024.